GlassScriptPhysician profile
Thomas C Merritt
NPI 1215927140
$2,562.50
in general payments reported to CMS, 2019-2025
25 companies · $45.16 in 2025
The $45.16 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,365 · 2020: $263 · 2021: $14.53 · 2022: $23.49 · 2023: $229 · 2024: $623 · 2025: $45.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $520.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $332.52 | 2019-2024 | Austedo Xr, Uzedy |
| Allergan, INC. | $217.08 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.64 | 2023-2024 | Caplyta |
| Avanir Pharmaceuticals, INC. | $165.32 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.05 | 2019-2025 | Trintellix |
| Abbvie INC. | $135.47 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $131.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $108.69 | 2019-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Vanda Pharmaceuticals INC. | $89.95 | 2019-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $70.37 | 2019-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $69.16 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $68.26 | 2023-2024 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $45.74 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $41.96 | 2023-2024 | Ingrezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $39.46 | 2024 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $37.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $36.35 | 2019-2024 | Rexulti |
| Shire North American Group INC | $31.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.65 | 2019 | |
| Tris Pharma INC | $19.96 | 2024 | Dyanavel Xr |
| Alfasigma USA, INC. | $18.35 | 2020 | |
| Neos Therapeutics, LP | $17.70 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $16.86 | 2024 | Secuado, Xelstrym |
| Bausch Health US, LLC | $13.64 | 2023 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Merritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.